Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) reached a new 52-week low on Wednesday . The company traded as low as C$1.20 and last traded at C$1.22, with a volume of 16001 shares. The stock had previously closed at C$1.22.
Analysts Set New Price Targets
Separately, Raymond James increased their price objective on shares of Oncolytics Biotech from C$3.00 to C$3.50 in a report on Friday, September 20th.
Read Our Latest Analysis on ONC
Oncolytics Biotech Stock Performance
Oncolytics Biotech (TSE:ONC – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of C($0.10). On average, analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- What is a support level?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 3 Warren Buffett Stocks to Buy Now
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Which Wall Street Analysts are the Most Accurate?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.